tazemetostat (Tazverik) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Accelerated Approval FDA Priority Review FDA
AACT DrugBank PubChem

Active Ingredient History

NOW
  • Now
Tazemetostat (EPZ-6438) is a selective inhibitor of histone-lysine N-methyltransferase EZH2. The drug is under clinical development (phase II) for the treatment of Diffuse Large B Cell Lymphoma, Malignant Mesothelioma and Synovial Sarcoma.   NCATS

Chemistry

  • SMILES: CCN(C1CCOCC1)C2=C(C)C(=CC(=C2)C3=CC=C(CN4CCOCC4)C=C3)C(=O)NCC5=C(C)C=C(C)NC5=O
  • InChIKey: NSQSAUGJQHDYNO-UHFFFAOYSA-N
  • Mol. Mass: 572.7376
  • ALogP: 4.73
  • ChEMBL Molecules:
    tazemetostat  
    tazemetostat hydrobromide  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$47.8581
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

tazemetostat

Organizations (40)

Research & Development (40)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (56)

Approved Indications (3)


 

Lymphoma, Follicular

Sarcoma

Soft Tissue Neoplasms (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (55)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 1/Phase 2)

Chordoma (Phase 2)

Colorectal Neoplasms (Phase 2)

COVID-19 (Phase 2)

Cytokine Release Syndrome (Phase 2)

Endometrial Neoplasms (Phase 2)

Ependymoma (Phase 2)

Glioma (Phase 2)

Hematologic Neoplasms (Phase 1)

Hepatoblastoma (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Hodgkin Disease (Phase 2)

Hydrolases (Phase 2)

Kidney Diseases (Phase 2)

Kidney Neoplasms (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1)

Liver Diseases (Phase 1)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, T-Cell (Phase 1)

Medulloblastoma (Phase 2)

Melanoma (Phase 1/Phase 2)

Mesothelioma (Phase 2)

Multiple Myeloma (Phase 1/Phase 2)

Mutation (Phase 2)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Nerve Sheath Neoplasms (Phase 2)

Neuroblastoma (Phase 2)

Neuroectodermal Tumors (Phase 2)

Osteosarcoma (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Early Phase 1)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Rhabdoid Tumor (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 3)

Sarcoma, Ewing (Phase 2)

Sarcoma, Synovial (Phase 2)

Small Cell Lung Carcinoma (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1/Phase 2)

Urinary Bladder Neoplasms (Phase 1/Phase 2)

Wilms Tumor (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 51
  • # of Trial Organizations: 40

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue